News & Events IR HOME NEWS & EVENTS OVERVIEW PRESS RELEASES EVENTS & PRESENTATIONS STOCK INFORMATION OVERVIEW HISTORIC STOCK LOOKUP INVESTMENT CALCULATOR ANALYST COVERAGE FINANCIALS & FILINGS OVERVIEW SEC FILINGS CORPORATE GOVERNANCE OVERVIEW MANAGEMENT BOARD OF DIRECTORS COMMITTEE COMPOSITION CONTACT IR IR HOME NEWS & EVENTS OVERVIEW PRESS RELEASES EVENTS & PRESENTATIONS STOCK INFORMATION OVERVIEW HISTORIC STOCK LOOKUP INVESTMENT CALCULATOR ANALYST COVERAGE FINANCIALS & FILINGS OVERVIEW SEC FILINGS CORPORATE GOVERNANCE OVERVIEW MANAGEMENT BOARD OF DIRECTORS COMMITTEE COMPOSITION CONTACT IR News & Events Press Releases May 23, 2023 Ardelyx, Inc. Reports Employment Inducement Grants Read More May 17, 2023 Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor) Read More May 15, 2023 Ardelyx, Inc. Reports Employment Inducement Grants Read More View All Press Releases Events & Presentations May 3, 2023 at 4:30 PM EDT Ardelyx Q1 2023 Earnings Call Mar 6, 2023 at 9:00 AM EST Cowen 43rd Annual Health Care Conference Mar 2, 2023 at 4:30 PM EST Ardelyx Fourth Quarter and Full Year 2022 Earnings Call View All Events FAQs Email Alerts Connect
News & Events Press Releases May 23, 2023 Ardelyx, Inc. Reports Employment Inducement Grants Read More May 17, 2023 Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor) Read More May 15, 2023 Ardelyx, Inc. Reports Employment Inducement Grants Read More View All Press Releases Events & Presentations May 3, 2023 at 4:30 PM EDT Ardelyx Q1 2023 Earnings Call Mar 6, 2023 at 9:00 AM EST Cowen 43rd Annual Health Care Conference Mar 2, 2023 at 4:30 PM EST Ardelyx Fourth Quarter and Full Year 2022 Earnings Call View All Events
May 17, 2023 Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor) Read More